Please login to the form below
GALACTIC-HF
This page shows the latest GALACTIC-HF news and features for those working in and with pharma, biotech and healthcare.
Amgen, Cytokinetics’ heart failure drug disappoints in phase 3
The results from the GALACTIC-HF study show that treatment with the drug, omecamtiv mecarbil, hit the primary endpoint of statistical significance on a measure of reduction in hospitalisation or other ... added. Amgen is set to present additional
Latest news
-
Trial of Amgen, Servier’s heart failure drug clears interim check
The GALACTIC-HF trial’s data monitoring committee has recommended that the 8, 200-patient study continue without any changes as it approaches a results readout by the end of the ... GALACTIC-HF should be sufficient to support approval of omecamtiv
-
Amgen, Servier heart failure drug clears trial hurdle
In the case of the GALACTIC-HF study of omecamtiv, the interim assessment was triggered by a pre-specific number of cardiovascular deaths, and the reviewing committee has concluded that the ... GALACTIC-HF is comparing omecamtiv with placebo when added
-
Amgen, Servier start second phase 3 trial of heart failure hope
outcome of the their already-running GALACTIC-HF study, which is due to complete enrollment in the first half of 2019 and generate results in early 2021. ... It will look at 20 weeks of treatment with placebo or the cardiac myosin activator on
More from news
Approximately 1 fully matching, plus 3 partially matching documents found.
Subscribe to our email news alerts
-
Pharmacovigilance Project Lead
- Highly competitive salary
-
Technical Sales Representative
- Highly competitive salary
-
Pharmacovigilance Manager
- Highly competitive salary
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
-
Senior Medical Writer
- Highly competitive salary
- Novo Nordisk suspended from ABPI over ‘serious’ code of practice breaches
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- Results for Astellas’ non-hormonal menopause drug published in The Lancet
- 2023 PM Society Awards – winners announced
- Biogen and Eisai’s Alzheimer’s drug to be covered by US Veterans Health Administration
- FDA external report recommends actions to address US opioid crisis
- MHRA to introduce new UK clinical trials framework
- Sanofi/Regeneron’s Dupixent approved by EC for atopic dermatitis in children
- Roche and Eli Lilly to collaborate on Alzheimer’s disease blood test
- Inizio appoints Stefanie Christmas as global head of DE&I
- Rare diseases: not so rare after all
- Sanofi/Regeneron’s Dupixent shows promise in atopic hand and foot dermatitis
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- Biogen and Eisai’s Alzheimer’s drug to be covered by US Veterans Health Administration
- Novo Nordisk suspended from ABPI over ‘serious’ code of practice breaches
- Dermavant reports positive phase 3 results for Vtama cream in atopic dermatitis
- Pfizer/BioNTech’s Omicron-adapted booster approved by FDA for young children
- Havas Health & You appoints Alex Okada as chief creative officer of Havas Lynx Group
PMHub
Medscape Medical Affairs
Medscape Medical Affairs enables all medical affairs professionals to take a more strategic leadership role, and maximize the impact of...
Latest intelligence
- Rare diseases: not so rare after all
- The brave new world addressing rare diseases – a way ahead to better and more inclusive treatment...
- Webinar: Evolving Patient Journeys - How to generate deeper insights in a changing healthcare landscape
- Register now for part one in a series, Evolving Patient Journeys, in which our experts look at the main ways in which the patient journey has evolved in recent years....
- DIGITAL EXPERIENCES: LEARNINGS FROM OUTSIDE PHARMA
- It’s long been the case that pharma lags behind other industries when it comes to digital adoption and engagement. So, what can we learn from these other industries, and how...
